LCM
ANTX icon

Laurion Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Laurion Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,814
Closed -$142K – 561
2024
Q1 		$142K Hold
43,814
– – ﹤0.01% 479
2023
Q4 		$898K Buy
+43,814
New +$733K 0.01% 352

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laurion Capital Management's ANTX Position: Q2 2024 in Review

Laurion Capital Management sold out of AN2 Therapeutics (ANTX) in Q2 2024, closing a stake of 43,814 shares — an estimated $142K sold.

Laurion Capital Management first reported a position in ANTX in Q4 2023 and held it in 2 quarters. The position peaked at $898K in Q4 2023. 45 funds tracked by Wall St. Rank hold ANTX as of Q2 2024.

  • Laurion Capital Management reported no remaining AN2 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 43,814 AN2 Therapeutics shares in Q2 2024, an estimated $142K.
  • Laurion Capital Management first reported a position in AN2 Therapeutics in Q4 2023 and held it in 2 quarters.
  • Laurion Capital Management's AN2 Therapeutics position peaked at $898K in Q4 2023.
  • 45 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.